Antibody-drug conjugates

Abstract

If the target has suitable properties, efficient drug delivery to malignant cells through ADCs minimizes drug exposure in normal tissues, increasing the therapeutic index of the attached cytotoxic drug. GO and BV were granted conditional approval, although the New Drug Application for GO was later (voluntarily) withdrawn due to a negative Phase III result. On February 22 2013, the FDA approved T-DM1 for use as a single agent for the treatment of patients with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.